WO2009118765A3 - Novel monoamine re-uptake inhibitor - Google Patents

Novel monoamine re-uptake inhibitor Download PDF

Info

Publication number
WO2009118765A3
WO2009118765A3 PCT/IN2009/000202 IN2009000202W WO2009118765A3 WO 2009118765 A3 WO2009118765 A3 WO 2009118765A3 IN 2009000202 W IN2009000202 W IN 2009000202W WO 2009118765 A3 WO2009118765 A3 WO 2009118765A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
polymorphs
prodrugs
solvates
metabolites
Prior art date
Application number
PCT/IN2009/000202
Other languages
French (fr)
Other versions
WO2009118765A8 (en
WO2009118765A2 (en
Inventor
Satinder Vir Kessar
Shrinivas Krishnarao Kulkarni
Rajesh Jain
Sanjay Trehan
Sitaram Kumar Magadi
Jagattaran Das
Gurmeet Kaur
Kamal Nain Singh
Sneh Lata
Ashish Dhir
Original Assignee
Panacea Biotec Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Limited filed Critical Panacea Biotec Limited
Publication of WO2009118765A2 publication Critical patent/WO2009118765A2/en
Publication of WO2009118765A8 publication Critical patent/WO2009118765A8/en
Publication of WO2009118765A3 publication Critical patent/WO2009118765A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system that are responsive to inhibition of biogenic amines, in particular one or more, or any combination of serotonin, norepinephrine and dopamine.
PCT/IN2009/000202 2008-03-28 2009-03-27 Novel monoamine re-uptake inhibitor WO2009118765A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN821/DEL/2008 2008-03-28
IN821DE2008 2008-03-28

Publications (3)

Publication Number Publication Date
WO2009118765A2 WO2009118765A2 (en) 2009-10-01
WO2009118765A8 WO2009118765A8 (en) 2010-09-10
WO2009118765A3 true WO2009118765A3 (en) 2010-10-28

Family

ID=41114419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000202 WO2009118765A2 (en) 2008-03-28 2009-03-27 Novel monoamine re-uptake inhibitor

Country Status (1)

Country Link
WO (1) WO2009118765A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP2014520776A (en) 2011-07-04 2014-08-25 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー Use of substituted isoquinolinones, isoquinoline diones, isoquinoline triones and dihydroisoquinolinones or their salts in each case as active agents against abiotic stresses in plants
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US10087404B2 (en) * 2014-09-19 2018-10-02 Kuraray Co., Ltd. Biological corrosion inhibitor for metals
CN106995410B (en) * 2016-01-26 2021-03-02 江苏恩华药业股份有限公司 Lactam derivative and application thereof
MX2018016227A (en) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Combination therapies.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466604A1 (en) * 2003-04-09 2004-10-13 Les Laboratoires Servier Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems
WO2006020049A2 (en) * 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007072041A1 (en) * 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466604A1 (en) * 2003-04-09 2004-10-13 Les Laboratoires Servier Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems
WO2006020049A2 (en) * 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007072041A1 (en) * 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KESSAR, S. V.: "'Counter-intuitive' regioselectivity, subtle steric and salvation effects in lithiation of cyclic tertiary aralkylamines.", TETRAHEDRON LETTERS, vol. 46, 2005, pages 6753 - 6755 *
SOMEI, M. ET AL.: "Titanium (III) chloride for the reduction of heteroaromatic and aromatic nitro compounds.", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 28, no. 8, 1980, pages 2515 - 2518 *

Also Published As

Publication number Publication date
WO2009118765A8 (en) 2010-09-10
WO2009118765A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009118765A3 (en) Novel monoamine re-uptake inhibitor
WO2007081857A3 (en) Cycloalkylamines as monoamine reuptake inhibitors
MX2009012685A (en) Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors.
WO2009093269A9 (en) Novel heterocyclic compounds
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
MX2008013583A (en) Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them.
WO2013038429A3 (en) Novel sglt inhibitors
NO20080981L (en) Nitrocatechol derivatives as COMT inhibitors
MY158339A (en) DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
MX368368B (en) Indole and indazole compounds as an inhibitor of cellular necrosis.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2008157751A3 (en) Substituted imidazoheterocycles
WO2010088050A3 (en) Bicyclic pyrazolo-heterocycles
WO2010150281A3 (en) Novel azabicyclohexanes
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
BRPI0612072A2 (en) aspartyl protease inhibitors
PH12014502586A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
MX353209B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE.
WO2010043953A3 (en) Novel bridged cyclic compounds as histone deacetylase inhibitors
GEP20135806B (en) Lactams as beta secretase inhibitors
WO2012172566A3 (en) Novel sglt inhibitors
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
MX2020001531A (en) Novel heterocyclic compounds as cdk8/19 inhibitors.
MX2011013507A (en) Novel gpr 119 agonists.
MX2012000685A (en) 3-phenoxymethylpyrrolidine compounds.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09725049

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09725049

Country of ref document: EP

Kind code of ref document: A2